OBJECTIVES: We sought to examine the effects of @entity14503 ( @entity29385 infusion on hemodynamic status, cardiovascular hormones, and renal function in healthy @entity1 . BACKGROUND: @entity29385 is a vasoactive and cardioprotective peptide belonging to the corticotrophin-releasing factor peptide family. Recent reports indicate the urocortins exert important effects beyond the hypothalamo-pituitary-adrenal axis upon cardiovascular and vasohumoral function in health and @entity299 . METHODS: We studied 8 healthy unmedicated @entity1 on 3 separate occasions 2 to 5 weeks apart. Subjects received placebo, 25-microg low-dose (LD), and 100-microg @entity2101 ( @entity2101 ) of @entity29385 intravenously over the course of 1 h in a single-blind, placebo-controlled, dose-escalation design. Noninvasive hemodynamic indexes, neurohormones, and renal function were measured. RESULTS: The administration of @entity29385 dose-dependently increased cardiac output (mean peak increments +/- SEM) (placebo 0.5 +/- 0.2 l/min; LD 2.1 +/- 0.6 l/min; @entity2101 5.0 +/- 0.8 l/min; p < 0.001), heart rate (placebo 3.3 +/- 1.0 beats/min; LD 8.8 +/- 1.8 beats/min; @entity2101 17.8 +/- 2.1 beats/min; p < 0.001), and left ventricular ejection fraction (placebo 0.6 +/- 1.4%; LD 6.6 +/- 1.5%; @entity2101 14.1 +/- 0.8%; p < 0.001) while decreasing systemic vascular resistance (placebo -128 +/- 50 dynes x s/cm(5); LD -407 +/- 49 dynes x s/cm(5); @entity2101 -774 +/- 133 dynes.s/cm(5); p < 0.001). Activation of plasma @entity916 activity (p = 0.002), @entity2178 (p = 0.001), and @entity1063 (p < 0.001) occurred only with the higher 100-mug dose. Subtle decreases in urine volume (p = 0.012) and natriuresis (p = 0.001) were observed. CONCLUSIONS: Brief intravenous infusions of @entity29385 in healthy @entity1 induced pronounced dose-related increases in cardiac output, heart rate, and left ventricular ejection fraction while decreasing systemic vascular resistance. Subtle renal effects and activation of plasma @entity916 , @entity2178 , and @entity1063 (at @entity2101 only) were observed. These findings warrant further investigation of the role of @entity29385 in circulatory regulation and its potential therapeutic application in @entity299 .

XXXX infusion in healthy @entity1 : hemodynamic, neurohormonal, and renal responses.

@entity14503 :: ('7349', 'Gene') :: ['urocortin'] @entity1 :: ('9606', 'Species') :: ['humans', 'men'] @entity2178 :: ('183', 'Gene') :: ['angiotensin II'] @entity2101 :: ('MESH:C538394', 'Disease') :: ['HD', 'high-dose'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac disease', 'heart disease'] @entity916 :: ('5972', 'Gene') :: ['renin'] @entity1063 :: ('MESH:D009638', 'Chemical') :: ['norepinephrine'] @entity29385 :: ('90226', 'Gene') :: ['Urocortin 2', 'UCN) 2', 'UCN 2']
@entity29385 :: (90226,Gene) :: ['Urocortin 2']
